Longer Premarket Reviews Don’t Mean Fewer Safety Issues: Canadian Study

While European regulators approve new drugs at a faster clip than their Canadian counterparts, both jurisdictions pull drugs from the market for safety reasons at the same rate, a new study finds.
International Pharmaceutical Regulatory Monitor